Atea Pharmaceuticals (AVIR) Net Cash Flow (2019 - 2026)

Atea Pharmaceuticals' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$16.4 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 129.98% year-over-year to -$16.4 million; the TTM figure through Mar 2026 stood at -$40.1 million (up 3.47% YoY), while the FY2025 annual figure was $31.0 million, up 139.2% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$16.4 million, down from $18.4 million in the prior quarter.
• The five-year high for Net Cash Flow was $82.5 million in Q2 2024, with the low at -$508.1 million in Q3 2022.
• The 5-year median for Net Cash Flow is -$10.4 million (2025), against an average of -$40.3 million.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow slumped 2271.42% in 2022, then surged 428.28% in 2024.
• Atea Pharmaceuticals' Net Cash Flow stood at $11.9 million in 2022, then plunged by 50.29% to $5.9 million in 2023, then plunged by 668.76% to -$33.8 million in 2024, then jumped by 154.4% to $18.4 million in 2025, then tumbled by 189.26% to -$16.4 million in 2026.
• Business Quant data shows AVIR's Net Cash Flow at -$16.4 million in Q1 2026, $18.4 million in Q4 2025, and -$10.4 million in Q3 2025.